7 updates from pubmed as at May 16th - ovarian cancer

Blogger's Note:  Sent on Thursday, 2013 May 16 (some duplicates from previously posted individually to blog)

PubMed Results

Items 1 - 7 of 7

1.	Correction: Potential Role of Estrogen Receptor Beta as a Tumor Suppressor of Epithelial Ovarian Cancer.
	Bossard C, Busson M, Vindrieux D, Gaudin F, Machelon V, Brigitte M, Jacquard C, Pillon A, Balaguer P, Balabanian K, Lazennec G.
	PLoS One. 2013 May 10;8(5). doi: 10.1371/annotation/480acc26-456b-4e06-8cb6-2834bd6f5553. Print 2013.
	PMID: 23675394 [PubMed - as supplied by publisher]

2.	Correction: Associations between Gene Expression Variations and Ovarian Cancer Risk Alleles Identified from Genome Wide Association Studies.
	Zhao H, Shen J, Wang D, Guo Y, Gregory S, Medico L, Hu Q, Yan L, Odunsi K, Lele S, Liu S.
	PLoS One. 2013 May 10;8(5). doi: 10.1371/annotation/febad39e-58f0-4562-a687-1fee2a7d1eff. Print 2013.
	PMID: 23675393 [PubMed - as supplied by publisher]

3.	Multicentre external validation of IOTA prediction models and RMI by operators with varied training.
	Sayasneh A, Wynants L, Preisler J, Kaijser J, Johnson S, Stalder C, Husicka R, Abdallah Y, Raslan F, Drought A, Smith AA, Ghaem-Maghami S, Epstein E, Van Calster B, Timmerman D, Bourne T.
	Br J Cancer. 2013 May 14. doi: 10.1038/bjc.2013.224. [Epub ahead of print]
	PMID: 23674083 [PubMed - as supplied by publisher]

4.	The in vitro antitumor activity of Siegesbeckia glabrescens against ovarian cancer through suppression of receptor tyrosine kinase expression and the signaling pathways.
	Cho YR, Choi SW, Seo DW.
	Oncol Rep. 2013 May 15. doi: 10.3892/or.2013.2468. [Epub ahead of print]
	PMID: 23673404 [PubMed - as supplied by publisher]

5.	The use of CT findings to predict extent of tumor at primary surgery for ovarian cancer.
	Glaser G, Torres M, Kim B, Aletti G, Weaver A, Mariani A, Hartmann L, Cliby W.
	Gynecol Oncol. 2013 May 11. doi:pii: S0090-8258(13)00740-3. 10.1016/j.ygyno.2013.05.007. [Epub ahead of print]
	PMID: 23672930 [PubMed - as supplied by publisher]

6.	Optimal (≤ 1cm) but Visible Residual Disease: Is Extensive Debulking Warranted?
	Barlin JN, Long KC, Tanner EJ, Gardner GJ, Leitao MM, Levine DA, Sonoda Y, Abu-Rustum NR, Barakat RR, Chi DS.
	Gynecol Oncol. 2013 May 11. doi:pii: S0090-8258(13)00739-7. 10.1016/j.ygyno.2013.05.006. [Epub ahead of print]
	PMID: 23672929 [PubMed - as supplied by publisher]

7.	Chemoresistance in ovarian cancer linked to expression of microRNAs.
	Frederick P, Green H, Huang J, Egger M, Frieboes H, Grizzle W, McNally L.
	Biotech Histochem. 2013 May 15. [Epub ahead of print]
	PMID: 23672416 [PubMed - as supplied by publisher]